(Reuters) - Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's rival ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

Madrigal Pharmaceuticals said on Wednesday it has entered into a licensing agreement worth up to $2 billion with China's CSPC Pharmaceutical Group to develop an oral GLP-1 drug for a serious form of ...

Adverse events leading to trial discontinuation were 2.6% for the semaglutide group and 3.3% for the placebo group. 1 Semaglutide 2.4 mg is not approved in the US for the treatment of MASH.

The bottom line For the millions of Americans living with fatty liver disease, particularly those with the more severe form known as MASH, semaglutide represents a promising new treatment option.

Semaglutide is not approved to treat MASH in the U.S. Pharmaceutical maker Novo Nordisk has said it plans to seek regulatory approval for its use in treating liver disease sometime this year.

Semaglutide 2.4 mg is not approved in the US to treat MASH. Novo Nordisk expects to file for regulatory approvals in the US in the first half of 2025. About ESSENCE (semaglutide 2.4 mg) ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a serious form of fatty liver disease, a new study has found.

Search for Symbols, analysts, keywords Log in ESSENCE phase 3 trial of semaglutide showed significant improvements at 72 weeks in adults with MASH, published in NEJM Apr. 30, 2025 5:31 PM ET ...

RICHMOND, Va., April 30, 2025 (GLOBE NEWSWIRE) -- An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and ...